Buscar recursos académicos

Abstract Background The rising global aging population has increased the prevalence of Alzheimer’s disease (AD), a condition with limited treatment options, making non-pharmacological interventions essential. While mob...

Abstract Purpose This study aimed to identify the effectiveness of free water MRI (FW-MRI) features for predicting amyloid-beta (Aβ) statuses in Alzheimer’s disease (AD) by constructing diagnostic models using machine...

Abstract Background Blood-based biomarkers could improve the precision of Alzheimer’s disease (AD) clinical diagnosis and expand access to targeted treatments. Therefore, we evaluated the diagnostic accuracy of plasma ...

Abstract Background Current understanding of the fluid biomarker profile in early-onset Alzheimer’s disease (EOAD) associated with pathogenic APP variants remains limited. We characterized four EOAD pedigrees carrying ...

Abstract Background Plasma glial fibrillary acidic protein (GFAP) has emerged as a promising biomarker of astrocytic reactivity in preclinical Alzheimer´s Disease (AD). However, most evidence to date comes from ultrasen...

Abstract Background Alzheimer’s disease (AD) is a progressive neurodegenerative disorder. Its complex pathogenesis remains unclear, and no specific drugs are available for treatment. Current treatments focus mainly on ...

Abstract Background Recruitment and retention remain persistent challenges in Alzheimer’s disease (AD) clinical trials, particularly as studies increasingly focus on earlier disease stages and require longer participat...

Abstract Background Telomere length (TL), a biomarker of biological aging, but its association with Alzheimer’s disease (AD) remains unclear. Methods We estimated TL in whole-genome sequencing data from 35,014 Alzheime...

Abstract Alzheimer’s disease (AD) is a prevalent and progressive neurodegenerative disease characterized by behavioral abnormalities, memory loss, and cognitive decline, presenting significant challenges for early diag...

Abstract Background ADAM10 and ADAM17, members of the membrane-bound disintegrin metalloproteinase (ADAM) family, act as α-secretases in the non-amyloidogenic processing of the amyloid precursor protein. While alteratio...

Abstract Background Triggering receptor expressed on myeloid cell-2 (TREM2) signaling promotes disease-associated microglia (DAM) and phagocytosis in neurodegenerative diseases. Traditional anti-TREM2 agonist antibodies ...

Abstract Background Tauopathies are a group of neurodegenerative diseases, including Alzheimer’s disease (AD), characterized by progressive accumulation of pathological Tau proteins. Among the diverse Tau species, trun...

Abstract Background Alzheimer’s disease (AD) is a growing global health concern, and emerging evidence suggests that oral health—particularly tooth loss—may be linked to cognitive decline. While implant therapy eff...

Abstract Accumulation of amyloid beta 1–42 (Aβ42) peptide in the extracellular space in the brain is a major observation in Alzheimer’s Disease (AD)-related pathology. Astrocytes are known to play pivotal role in cl...

Abstract Mutations in the presenilin (PS/PSEN) genes cause early-onset familial Alzheimer’s disease (AD) by enhancing cerebral accumulation of amyloid-β (Aβ) peptides and microtubule-associated protein tau (MAPT). Ho...

Abstract Background Anti-amyloid monoclonal antibodies are entering clinical practice for early symptomatic Alzheimer’s disease (AD), but European real-world data on feasibility, safety, and biomarker monitoring remain...

Abstract Neuroinflammation is a key pathogenic factor for neurodegenerative diseases. Mesenchymal stem cell (MSC) transplantation, as a potential strategy for regulating neuroinflammation, has received extensive attentio...

Abstract Background As dementia cases continue to rise, effective prevention strategies are urgently needed. However, objective biomarkers that directly reflect lifestyle factors remain limited. Life’s Essential 8 (LE8...